PathAI And Moffitt Cancer Center Announce Strategic Collaboration To Deploy AISight® Dx Digital Pathology Platform & Advance The Use Of AI In Diagnostics

PathAI, a global leader in artificial intelligence and digital pathology solutions, has announced a multi-year strategic collaboration with Moffitt Cancer Center, one of the nation’s leading cancer hospitals and a recognized pioneer in cancer research. This collaboration will focus on deploying PathAI’s digital pathology platform, AISight® Dx, across Moffitt’s pathology programs with the goal of transforming cancer detection and driving innovation in diagnostics and research.

AISight® Dx is a cloud-native digital pathology image management system developed by PathAI. The platform is built to serve both laboratory workflow needs and translational research applications. It offers enterprise-scale slide management, advanced image viewing, and seamless collaboration tools, all enhanced with integrated AI capabilities. By combining these features, AISight® Dx enables laboratories to achieve greater efficiency, while also delivering improved speed and accuracy in pathology processes.

Andy Beck, MD, PhD, CEO and Co-Founder of PathAI, stated, “We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care. By deploying AISight® Dx and building this strategic partnership, we’re equipping Moffitt’s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.”

Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center, mentioned, “This collaboration aligns perfectly with Moffitt’s mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation. By deploying AISight® Dx into our pathology infrastructure, we’re taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review.

William Westra, MD, vice chair of Pathology at Moffitt Cancer Center, said, “Adopting cutting-edge digital pathology technologies is key to driving Moffitt’s vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care. By partnering with PathAI, we’re laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI’s and Moffitt’s legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.”

As part of this collaboration, PathAI and Moffitt Cancer Center will also establish a framework for joint research programs. This includes the collation of real-world multimodal data, the development of initiatives to support clinical trials and pharmaceutical collaborations, and the co-creation of next-generation AI-based diagnostic solutions. These efforts aim to advance precision medicine and broaden the impact of digital pathology and AI in clinical practice.

Through this partnership, PathAI and Moffitt Cancer Center seek to redefine the role of digital pathology in cancer care by uniting cutting-edge technology with clinical expertise. The collaboration sets a new precedent for how advanced digital platforms and artificial intelligence can be leveraged to bring meaningful improvements to cancer diagnostics and patient outcomes.